PL1653964T3 - Skojarzone leczenie raka obejmujące AZD2171 i ZD1839 - Google Patents

Skojarzone leczenie raka obejmujące AZD2171 i ZD1839

Info

Publication number
PL1653964T3
PL1653964T3 PL04743287T PL04743287T PL1653964T3 PL 1653964 T3 PL1653964 T3 PL 1653964T3 PL 04743287 T PL04743287 T PL 04743287T PL 04743287 T PL04743287 T PL 04743287T PL 1653964 T3 PL1653964 T3 PL 1653964T3
Authority
PL
Poland
Prior art keywords
azd2171
human
combination therapy
cancer
antiangiogenic
Prior art date
Application number
PL04743287T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1653964T3 publication Critical patent/PL1653964T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04743287T 2003-07-10 2004-07-08 Skojarzone leczenie raka obejmujące AZD2171 i ZD1839 PL1653964T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0316127.0A GB0316127D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002944 WO2005004872A1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839
EP04743287A EP1653964B1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839

Publications (1)

Publication Number Publication Date
PL1653964T3 true PL1653964T3 (pl) 2009-01-30

Family

ID=27741907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04743287T PL1653964T3 (pl) 2003-07-10 2004-07-08 Skojarzone leczenie raka obejmujące AZD2171 i ZD1839

Country Status (24)

Country Link
US (2) US20060167024A1 (pl)
EP (1) EP1653964B1 (pl)
JP (1) JP2007526888A (pl)
KR (1) KR20060033785A (pl)
CN (1) CN100415236C (pl)
AT (1) ATE409039T1 (pl)
AU (1) AU2004255024B2 (pl)
BR (1) BRPI0412408A (pl)
CA (1) CA2531620C (pl)
DE (1) DE602004016754D1 (pl)
DK (1) DK1653964T3 (pl)
ES (1) ES2313033T3 (pl)
GB (1) GB0316127D0 (pl)
HK (1) HK1089667A1 (pl)
HR (1) HRP20080597T3 (pl)
IL (1) IL172683A0 (pl)
MX (1) MXPA06000412A (pl)
NO (1) NO20056170L (pl)
NZ (1) NZ544270A (pl)
PL (1) PL1653964T3 (pl)
PT (1) PT1653964E (pl)
SI (1) SI1653964T1 (pl)
WO (1) WO2005004872A1 (pl)
ZA (1) ZA200600184B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
BRPI0620118A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de azd2171 ou de um sal farmaceuticamente aceitável do mesmo e de permetrexed, composição farmacêutica, kit, e, método para a produção de um efeito de redução da permeabilidade antiangiogênica, e/ou vascular em um animal de sangue quente
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065515A2 (en) * 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
PL199802B1 (pl) * 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
CZ20023231A3 (cs) * 2000-03-31 2003-01-15 Angiogene Pharmaceuticals Ltd. Farmaceutické prostředky obsahující činidla poąkozující cévy
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
AU2003202094B2 (en) * 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds

Also Published As

Publication number Publication date
AU2004255024B2 (en) 2007-09-27
AU2004255024A1 (en) 2005-01-20
NZ544270A (en) 2007-09-28
MXPA06000412A (es) 2006-03-17
CN1819831A (zh) 2006-08-16
GB0316127D0 (en) 2003-08-13
HRP20080597T3 (en) 2008-12-31
PT1653964E (pt) 2008-11-24
CA2531620A1 (en) 2005-01-20
EP1653964A1 (en) 2006-05-10
US20100179142A1 (en) 2010-07-15
ZA200600184B (en) 2007-04-25
JP2007526888A (ja) 2007-09-20
DK1653964T3 (da) 2009-01-05
SI1653964T1 (sl) 2009-02-28
ATE409039T1 (de) 2008-10-15
CA2531620C (en) 2011-09-27
BRPI0412408A (pt) 2006-08-22
IL172683A0 (en) 2006-04-10
ES2313033T3 (es) 2009-03-01
NO20056170L (no) 2006-02-08
HK1089667A1 (en) 2006-12-08
KR20060033785A (ko) 2006-04-19
EP1653964B1 (en) 2008-09-24
CN100415236C (zh) 2008-09-03
US20060167024A1 (en) 2006-07-27
DE602004016754D1 (de) 2008-11-06
WO2005004872A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
EP1971338B8 (en) Combination of zd6474 and pemetrexed
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
ZA200600188B (en) Combination therapy
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
IL177953A0 (en) Combination therapy including azd2171 and a taxane
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine